All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion.
The final analysis will be limited to individuals in whom the volume of ICM administered during the index procedure was between 50 and 500 mL and for whom both pre- and post-procedure serum creatinine measurements were available.
The primary objective of the study is the effect of short-term and long-term SGLT2i therapy on the occurrence of CI-AKI in patients undergoing diagnostic or therapeutic procedures with ICM.
all consecutive patients who underwent PCI or coronary angiography during the study period for whom the variables required for the analysis are available
unavailability of variables required for the analysis, volume
contrast agent volume <50 mL or >500 mL.
Retrospective analysis of data obtained from patients hospitalized between 2020 and 2025 in the Department of Cardiology and Internal Medicine, who underwent coronary angiography or PCI. The final analysis will be limited to individuals in whom the volume of ICM administered during the index procedure was between 50 and 500 mL and for whom both pre- and post-procedure serum creatinine measurements were available
Case-control
Retrospective
Flozin
DrugPatients who underwent percutaneous coronary interventions while using empagliflozin or dapagliflozin
Occurrence of Contrast-Induced Acute Kidney Injury (CI-AKI)
Occurrence of CI-AKI defined as an increase in serum creatinine concentration of ≥0.5 mg/dL (44.2 μmol/L) or \>25% compared with baseline within 72 h after intravascular administration a contrast medium agent
Creatinine change after coronary procedure
Change in serum creatinine concentration before and after the index procedure
eGFR after coronary procedure
Change in eGFR before and after the index procedure
Real-life incidence of AKI
the true incidence of CI-AKI in real-world clinical setting
incidence of CI-AKI in diabetic patients
the effect of SGLTi on the occurrence of CI-AKI in patients with and without type 2 diabetes mellitus
Click on the lead sponsor to view all of their trials.
